MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461474 | Name: Azalanstat mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Azalanstat is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. Azalanstat has been shown to inhibit cholesterol synthesis in HepG2 cells, human fibroblasts, hamster hepatocytes and hamster liver, by inhibiting the cytochrome P450 enzyme lanosterol 14 alpha-demethylase. When administered orally to hamsters fed regular chow, RS-21607 (50 mg/kg/day) lowered serum cholesterol in a dose-dependent manner (ED50 = 62 mg/kg) in a period of 1 week. It preferentially lowered low density lipoprotein (LDL) cholesterol and apo B relative to high density lipoprotein (HDL) cholesterol and apo A-1.

Chemical Structure

Azalanstat mesylate
Azalanstat mesylate
CAS#143484-80-4 (mesylate)

Theoretical Analysis

MedKoo Cat#: 461474

Name: Azalanstat mesylate

CAS#: 143484-80-4 (mesylate)

Chemical Formula: C23H28ClN3O5S2

Exact Mass:

Molecular Weight: 526.06

Elemental Analysis: C, 52.51; H, 5.37; Cl, 6.74; N, 7.99; O, 15.21; S, 12.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
143484-82-6 (HCl) 143393-27-5 (free base) 143484-77-9 (sulfate) 143484-80-4 (mesylate) 143484-81-5 (phosphate) 143484-78-0 (maleate) 143484-79-1 (2 maleate)
Synonym
Azalanstat mesylate; Azalanstat; RS 21607; RS-21607; RS21607;
IUPAC/Chemical Name
4-((((2S,4S)-2-((1H-imidazol-1-yl)methyl)-2-(4-chlorophenethyl)-1,3-dioxolan-4-yl)methyl)thio)aniline mesylate
InChi Key
UILFTDNCRVIMRH-DTRWSJPISA-N
InChi Code
InChI=1S/C22H24ClN3O2S.CH4O3S/c23-18-3-1-17(2-4-18)9-10-22(15-26-12-11-25-16-26)27-13-20(28-22)14-29-21-7-5-19(24)6-8-21;1-5(2,3)4/h1-8,11-12,16,20H,9-10,13-15,24H2;1H3,(H,2,3,4)/t20-,22-;/m0./s1
SMILES Code
NC1=CC=C(SC[C@H]2O[C@@](CCC3=CC=C(Cl)C=C3)(CN4C=CN=C4)OC2)C=C1.OS(=O)(C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 526.06 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Burton PM, Swinney DC, Heller R, Dunlap B, Chiou M, Malonzo E, Haller J, Walker KA, Salari A, Murakami S, et al. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem Pharmacol. 1995 Aug 8;50(4):529-44. PubMed PMID: 7646560. 2: Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, Szarek WA. Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1457-61. PubMed PMID: 15713406. 3: Morisawa T, Wong RJ, Bhutani VK, Vreman HJ, Stevenson DK. Inhibition of heme oxygenase activity in newborn mice by azalanstat. Can J Physiol Pharmacol. 2008 Oct;86(10):651-9. doi: 10.1139/y08-069. PubMed PMID: 18841169. 4: Pittalà V, Salerno L, Romeo G, Modica MN, Siracusa MA. A focus on heme oxygenase-1 (HO-1) inhibitors. Curr Med Chem. 2013;20(30):3711-32. Review. PubMed PMID: 23746277. 5: Rahman MN, Vlahakis JZ, Roman G, Vukomanovic D, Szarek WA, Nakatsu K, Jia Z. Structural characterization of human heme oxygenase-1 in complex with azole-based inhibitors. J Inorg Biochem. 2010 Mar;104(3):324-30. doi: 10.1016/j.jinorgbio.2009.10.011. Epub 2009 Oct 24. Review. PubMed PMID: 19917515. 6: Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, Szarek WA. Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors. J Med Chem. 2006 Jul 13;49(14):4437-41. PubMed PMID: 16821802. 7: Ahmed H, McLaughlin BE, Soong J, Marks GS, Brien JF, Nakatsu K. The source of endogenous carbon monoxide formation in human placental chorionic villi. Cell Mol Biol (Noisy-le-grand). 2005 Oct 3;51(5):447-51. PubMed PMID: 16309566. 8: Vaknin KM, Lazar S, Popliker M, Tsafriri A. Role of meiosis-activating sterols in rat oocyte maturation: effects of specific inhibitors and changes in the expression of lanosterol 14alpha-demethylase during the preovulatory period. Biol Reprod. 2001 Jan;64(1):299-309. PubMed PMID: 11133687. 9: Rahman MN, Vukomanovic D, Vlahakis JZ, Szarek WA, Nakatsu K, Jia Z. Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds. J R Soc Interface. 2013 Jan 6;10(78):20120697. doi: 10.1098/rsif.2012.0697. Epub 2012 Nov 8. PubMed PMID: 23097500; PubMed Central PMCID: PMC3565801. 10: Wang C, Xie H, Song X, Ning G, Yan J, Chen X, Xu B, Ouyang H, Xia G. Lanosterol 14alpha-demethylase expression in the mouse ovary and its participation in cumulus-enclosed oocyte spontaneous meiotic maturation in vitro. Theriogenology. 2006 Sep 15;66(5):1156-64. Epub 2006 May 2. PubMed PMID: 16650467. 11: Walker KA, Kertesz DJ, Rotstein DM, Swinney DC, Berry PW, So OY, Webb AS, Watson DM, Mak AY, Burton PM, et al. Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering. J Med Chem. 1993 Jul 23;36(15):2235-7. PubMed PMID: 8340925. 12: Vlahakis JZ, Hum M, Rahman MN, Jia Z, Nakatsu K, Szarek WA. Synthesis and evaluation of imidazole-dioxolane compounds as selective heme oxygenase inhibitors: effect of substituents at the 4-position of the dioxolane ring. Bioorg Med Chem. 2009 Mar 15;17(6):2461-75. doi: 10.1016/j.bmc.2009.01.078. Epub 2009 Feb 12. PubMed PMID: 19268600. 13: Xie H, Xia G, Byskov AG, Andersen CY, Bo S, Tao Y. Roles of gonadotropins and meiosis-activating sterols in meiotic resumption of cultured follicle-enclosed mouse oocytes. Mol Cell Endocrinol. 2004 Apr 15;218(1-2):155-63. PubMed PMID: 15130520. 14: Hrboticky N, Becker A, Kruse HJ, Weber PC. Increased cellular triglyceride levels in human monocytic and rat smooth muscle cells after lovastatin. Biochim Biophys Acta. 1997 Nov 30;1349(3):211-21. PubMed PMID: 9434135. 15: Jin S, Zhang M, Lei L, Wang C, Fu M, Ning G, Xia G. Meiosis activating sterol (MAS) regulate FSH-induced meiotic resumption of cumulus cell-enclosed porcine oocytes via PKC pathway. Mol Cell Endocrinol. 2006 Apr 25;249(1-2):64-70. Epub 2006 Feb 24. PubMed PMID: 16500744. 16: Swinney DC, So OY, Watson DM, Berry PW, Webb AS, Kertesz DJ, Shelton EJ, Burton PM, Walker KA. Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo. Biochemistry. 1994 Apr 19;33(15):4702-13. PubMed PMID: 8161528. 17: Sloane DL, So OY, Leung R, Scarafia LE, Saldou N, Jarnagin K, Swinney DC. Cloning and functional expression of the cDNA encoding rat lanosterol 14-alpha demethylase. Gene. 1995 Aug 19;161(2):243-8. PubMed PMID: 7665087.